Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658600 | 0.86 | PDPK1 (0.48) | PDPK1MMP1L3MBTL1KMT2AMEN1 | |
| SCHEMBL658086 | 0.86 | NPC1 (0.54) | PDPK1ERCC5FEN1MMP1L3MBTL1 | |
| SCHEMBL657948 | 0.84 | PDPK1 (0.50) | PDPK1ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL657351 | 0.83 | PDPK1 (0.67) | PDPK1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL656362 | 0.83 | ALDH1A1 (0.48) | PDPK1L3MBTL1ALDH1A1 | |
| SCHEMBL657084 | 0.82 | PDPK1 (0.68) | PDPK1ERCC5FEN1MMP1L3MBTL1 | |
| SCHEMBL13385683 | 0.82 | PDPK1 (0.56) | PDPK1ERCC5FEN1MMP1L3MBTL1 | |
| SCHEMBL657975 | 0.78 | PDPK1 (0.69) | PDPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL657804 | 0.77 | SRD5A2 (0.38) | ERCC5FEN1MMP1L3MBTL1SRD5A2 | |
| SCHEMBL658184 | 0.75 | PDPK1 (0.49) | PDPK1L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | claimed |
| EP-1789052-A4 | COMPOSITION AND METHOD FOR INDUCING OR RESTORING LOCOMOTOR FUNCTIONS IN AN ANIMAL | UNIV LAVAL (CA) | 2008-05-21 | — | — | EP | claimed |
| US-20080096847-A1 | Composition And Method For Inducing Or Restoring Locomotor Functions In An Animal | UNIVERSITE LAVAL | 2008-04-24 | — | — | US | claimed |
| EP-1789052-A1 | COMPOSITION AND METHOD FOR INDUCING OR RESTORING LOCOMOTOR FUNCTIONS IN AN ANIMAL | Université Laval (CA) | 2007-05-30 | — | — | EP | claimed |
| WO-2006026850-A1 | COMPOSITION AND METHOD FOR INDUCING OR RESTORING LOCOMOTOR FUNCTIONS IN AN ANIMAL | UNIVERSITE LAVAL (CA) | 2006-03-16 | — | — | WO | claimed |
| US-20030187055-A1 | Synergistic pharmaceutical combinations for treating obesity | BANK OF AMERICA, N.A., AS AGENT | 2003-10-02 | — | — | US | claimed |
| US-20030162725-A1 | Synergistic pharmaceutical combinations for treating obesity with EGCG | BANK OF AMERICA, N.A., AS AGENT | 2003-08-28 | — | — | US | claimed |
| US-6579899-B1 | Precursor or prodrug of serotonin, tryptophan or 5-hydroxytryptophan | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2003-06-17 | — | — | US | claimed |
| WO-2002038141-A9 | COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INST TECHNOLOGY (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020173549-A1 | Compositions and methods for treatment of mild cognitive impairment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-21 | — | — | US | claimed |
| EP-1253915-A1 | METHOD FOR TREATING STRESS WITH A PRECURSOR OF SEROTONIN | Massachusetts Institute of Technology (US) | 2002-11-06 | — | — | EP | claimed |
| WO-2002038141-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| WO-2001054681-A2 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-08-02 | — | — | WO | claimed |
| US-9315483-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2001067890-A2 | COMPOSITION AND METHOD TO TREAT WEIGHT GAIN AND OBESITY ATTRIBUTABLE TO PSYCHOTROPIC DRUGS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001054681-A2 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | PDPK1 109/4885ERCC5 3532/4885FEN1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.